Back to today’s briefing

Story perspectives

Novo Nordisk Cuts Ties Amid GLP-1 Drug Controversy

6/28/2025

37 8

Summary

Story summary

Novo Nordisk has severed ties with Hims & Hers, citing concerns over the promotion of compounded GLP-1 drugs alongside its obesity treatment, Wegovy. The pharmaceutical giant accused Hims of misleading practices and raised alarms about the safety of compounded medications. Meanwhile, access to FDA-approved GLP-1s continues to be hindered by steep prices and insurance challenges.

1 of 1

Story summary

Novo Nordisk has severed ties with Hims & Hers, citing concerns over the promotion of compounded GLP-1 drugs alongside its obesity treatment, Wegovy. The pharmaceutical giant accused Hims of misleading practices and raised alarms about the safety of compounded medications. Meanwhile, access to FDA-approved GLP-1s continues to be hindered by steep prices and insurance challenges.